The A-to-Z factors associated with cognitive impairment. Results of the DeCo study.

Introduction: Cognitive impairment (CI) is known to be mediated by several risk and protective factors, many of which are potentially modifiable. Therefore, it is important to have up-to-date studies that address a standard assessment of psychosocial, clinical and lifestyle variables. Materials and methods: We conducted a cross-sectional observational study, with a 24-month timeframe, to estimate the relationship between risk and protective factors associated with dementia, according to the A-to-Z Dementia Knowledge. Participants were considered at CI risk if they tested positive for at least one of three validated CI screening tests: The Memory Impairment Screening, Short Portable Mental State Questionnaire, and Semantic Verbal Fluency. The A-to-Z data Collection included Mediterranean Diet Adherence Screener and Geriatric Depression Scale. Results: The estimated prevalence of CI was 22.6% in a sample of 709 patients with an average of 69.3±10.3 years. The risk factors gradually associated with cognitive decline were hypertension, loneliness, and depression. In contrast, the protective factors gradually associated with less cognitive decline were internet use, reading, and intellectually stimulating jobs. Finally, living alone, having diabetes, taking benzodiazepines, and sleeping more than 9 h were statistically significant associated with CI, whereas to do memory training or a family history of dementia was characteristic of patients without CI. Conclusion: A joint assessment of the influence of psychosocial, clinical, and lifestyle-related factors is needed to develop dementia prevention strategies.

Detección e intervención en personas de riesgo depadecer diabetes en farmacias comunitarias de laprovincia de Valencia (DETECTA SUCRE) / Detection and intervention of people at risk of diabetes in community pharmacies of Valencia

Objetivo: detectar personas en riesgo alto o muy alto de padecer diabetes mellitus tipo 2 (DM2) o alteraciones del metabolismo de los hidratos de carbono, derivación para posible diagnóstico al médico yrealizar una intervención educativa.Métodos: estudio observacional transversal y longitudinal prospectivo con intervención educativa en farmacias comunitarias situadas en la provincia de Valencia entre junio y noviembre de 2018. Se incluyeronusuarios de las farmacias comunitarias, mayores de 18 años, no diagnosticados de DM2 que aceptaron realizar la encuesta. Muestreo no probabilístico.Variable principal: puntuación en el test Findrisc, determinación capilar (si F≥15), intervención y número de diagnósticos de DM2 y preDM2. Las diferencias entre grupos se calcularon con el test de chi-cuadrado, t de Student o de Wilcoxon.Resultados: el estudio se realizó en 25 farmacias. La muestra incluyó a 752 usuarios. De ellos, 148 (19,7%) tenían alto o muy alto riesgo de DM2 (F≥15). Se realizaron 118 determinaciones capilares válidas (22 no aceptaron y 8 no la repitieron), 78 (10,4%) tuvieron resultados superiores a los normales y a 48 (6,4%) se les derivó al médico. 32 de estos no fueron al médico o no informaron al farmacéutico del resultado. De los 16 que conocemos el resultado, 12 (1,6%) fueron diagnosticados de diabetes o prediabetes.Conclusiones: los resultados de este estudio piloto dejan entrever la utilidad de la farmacia comunitaria como agente con un papel importante en el cribado de DM2 al detectar el presente trabajo casi un20% de usuarios con un riesgo elevado de padecer la enfermedad.

Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance.

Medication adherence is a priority for health systems worldwide and is widely recognised as a key component of quality of care for disease management. Adherence-related indicators were rarely explicitly included in national health policy agendas. One barrier is the lack of standardised adherence terminology and of routine measures of adherence in clinical practice. This paper discusses the possibility of developing adherence-related performance indicators highlighting the value of measuring persistence as a robust indicator of quality of care. To standardise adherence and persistence-related terminology allowing for benchmarking of adherence strategies, the European Ascertaining Barriers for Compliance (ABC) project proposed a Taxonomy of Adherence in 2012 consisting of three components: initiation, implementation, discontinuation. Persistence, which immediately precedes discontinuation, is a key element of taxonomy, which could capture adherence chronology allowing the examination of patterns of medication-taking behaviour. Advances in eHealth and Information Communication Technology (ICT) could play a major role in providing necessary structures to develop persistence indicators. We propose measuring persistence as an informative and pragmatic measure of medication-taking behaviour. Our view is to develop quality and performance indicators of persistence, which requires investing in ICT solutions enabling healthcare providers to review complete information on patients' medication-taking patterns, as well as clinical and health outcomes.